Immutep
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
33 Australia Sq L 264, Sydney, New South...Phone Number
+61 283157003Website
www.immutep.comRevenue
-Stock Symbol
IMMPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
2
1
1
About Immutep
Established in 2001, Immutep is headquartered in Sydney, New South Wales. They are a biotechnology company working in the field of cancer immunotherapy.Explore more
Immutep Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immutep your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Immutep, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immutep
Funding: Get notified immidiatlly once Immutep has new funding data
Check if Immutep has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Immutep launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Immutep recently announced quarterly report
Check out if Immutep is spiking on competitors!
Click to see if Immutep had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Immutep
Find more new buyers
Compare Similar Companies to Immutep
Compare insights from companies similar to Immutep, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immutep is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immutep is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immutep.
Immutep financials insights
Gather financial insights about Immutep, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Share Placement
$7M
2023
Other Financing Round
$80M
2024
Other Financing Round
$53M
Immutep Tech Stack
A closer look at the technologies used by Immutep
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
Product Development, Research & Development, Governmental Affairs & Regulation, Medical Research, Clinical Operations, Regulations
Funding
Funding
Partnership
Partnership, Product Development, Clinical Operations
Partnership
Partnership, Research & Development, Product Management, Logistics / Supply Chain, Medical Research, Clinical Operations
Immutep News & Media
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)
Immutep Shareholders Between March 24, 2025 and March 12, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder LawsuitImmutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
SYDNEY, AUSTRALIA, June 04, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology (EULAR) Congress, in London, UK on 4th June 2026 at 1.30 pm UK time in a poster session.Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP
LOS ANGELES, June 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immutep
Sign Up For FreeTo access detailed company insights
Established in 2001, Immutep is headquartered in Sydney, New South Wales. They are a biotechnology company working in the field of cancer immunotherapy.... Read More
